Protokoly_diagnostiki_i_lechenia_zabolevany
.pdf4.Hanus PM, Danzinger LH. Treatment of chronic bacterial prostatitis. Clin Pharm 1984; 3: 49-55;
5.McNaughton, C.M. and Wilt, T. (2001) Allopurinol for chronic prostatitis (Cochrane Review). The Cochrane Library (Issue 1). Oxford: Update Software;
6.Collins M, MacDonald R, Wilt T. Diagnosis and treatment of chronic abacterial prostatitis: a systematic review. Ann Intern Med 2000; 133: 367-368;
7.McNaughton Collinns M, MacDonald R, Wilt T. Interventions for chronic abacterial prostatitis. In: The Cochrane Library, Issue 3, 2001.
* – , # (% % ) .
;: 02-018
"$ &: " :
& !: ' @, .
' & & ( ): 9
(: H40.5 "
) : " – , $#(' @), ,$# " ( 3 ) & & & "" .
$ :
$ %$, ,, $ ' @, %$ & " .
%$: " , " , ".
: % , $& , .
' @: & , & ,, .
$ ' @: , ; & ,' @.
% & : " & , , , & .
"$ ( & ): , . * : . ". B$# " % . . ! . ! &. & .
" :
" : " $# , & , ' @
5 : 7 , & , , , , , ?6, ? , , , ?J;,
?!;, 'BL, $, 3 , & . |
|
|
||||
|
: ' @, |
& |
, |
|
|
, |
" , % |
|
, |
% |
|
, |
|
3 & . |
|
|
|
|
|
|
" & |
: |
|
|
|
|
2.<
3.;
7.&
8.&
" & & :
1.H)B
2.7
3.B " " &
4.7
5." B J
6.;
8. ' ( )
9.?J;
10.?!;
11.'BL
+ :
1. # % ' @ –250 1 4 & 1-3 , 0,5% 2 & -1-3 ; 1-2 &, 1-3 , 20% 2 / 1 & 1-3 ; .
2. H $# – 3& 3 B J.% & # , .
: 6 ": , ' @, , % @ :
13.42 6 " " 13.20 ' 3 3 12.64 ; 3 %
13.71 ' 3
|
|
|
|
|
|
||
12.31 |
J |
|
|
|
|
|
|
12.14 |
@ 3 ( ) |
|
|
|
|||
1. |
|
3 |
|
" |
|||
& 3 " . |
|
|
|
||||
2. |
|
? & |
|
& |
|
|
|
& % – 0,25% 4 & – 70,1% 1 6 & & -7 , & – - 1
1 & – 3 , , 25 1 3 & 7-10 . |
|
|
||||||||||
3. |
|
% |
|
|
- |
& |
||||||
|
& $# |
: |
0,5-1 |
& |
||||||||
V - 8 , 2 |
4 & 6-9 , |
|
||||||||||
1 |
3 & 5-8 , |
& V 0,5 7 ; |
||||||||||
/ V 1 2 & 7 , |
$ 40% , |
|||||||||||
5% 0,5 |
& |
4,0 " , 0,02% 2 6 |
||||||||||
&. |
|
|
|
|
|
|
|
|
|
|
|
|
|
% |
3 |
|
" |
|
|
||||||
|
90 1 & 6-9 . |
|
|
|
|
|
||||||
4. . |
|
|
|
|
|
|
|
|
|
|
||
" - " 7 , |
% " - 10 . |
|||||||||||
" & : |
|
|
|
|
|
|
|
|||||
1. *@ & % |
20 |
|
|
|
|
2.*G
3.*@ ( ) 0,1% 10
4.*@ 25 , 100 , 150 ,
5.* V 1 /30
6. |
*? ( ) ( & ) 0,1%, 0,5%, 1% 1 |
7. |
* V 40 / , 80 /2 |
8.@
9.*? V 5%, 10% 2 , 5
10.*+
11.* V 30 /
12.*; 0,5%, 1% 5
" & & :,- !: ' @
/ , & :
1.EBM Guidelines. Glaucoma. 2004.
2.Rossetti L., Marchetti I., Orzalesi N. Randomised clinical trials on medical treatvent of glaucoma: are they appropriare to guide clinical practice? // Arch. Ophalmol/ - 1993, 111: 96-103.
3.Glaucoma Laser Trial Group. The glaucoma laser trial (GLT) and glaucoma laser trial follow-up study: results. Am. J. Ophtalmol 1995, 120: 718-731.
4.Migdal C, Gregory W., Hitchins R., Kolker AE. Long-term functional outcome after early surgery compared with laser and medicine in open angle glaucoma. Ophthalmology 1994, 105: 1651-1657.
5.Collaborative normal-tension glaucoma study group. The effectiveness of intraocular pressure reduction in the treatment of normal 0tension glaucoma. Am.J.Ophtalmol 1998, 126: 498-505.
6.Edwards RS. A comparative study of Ocuset Pilo 40, intensive pilocarpine and low-dose pilocarpine in the initial treatment of primary acute angle-closure glaucoma. Curr Med Res Opin 1997, 13: 501-509.
* – , # (% % ) .
;
: 22-177
"$ &: " :
& ! : , % . " , ,, 3 % " #- (-, -) , " . # & " " .
' & & ( ): 30
(:
;84 % , " ,
M86
) : G " – 3 , $# "-" " # ( ), & #$#
, |
, %$. |
|
|||
$ : |
& $: |
|
|||
1) |
|
; 2) & ; 3) |
" |
||
& ; 4) ; 5) |
|
||||
. |
|
|
|
||
$ $ (J !.?.): |
|||||
?. |
, % : |
||||
1. |
|
|
|
|
|
2. |
|
|
% |
|
|
3. |
|
|
" |
|
|
<. |
: |
|
|
2.:
" ( , % , 3 .)
(-, -, , 3 )
– , , .
+ % ( % , -, % )
! "
'. " :
2."
3."
4.-3 "
5."
. " "$:
3.G "
>. % :
1.6 :
O %
+ %
2.# :
?
?
+
!
D. :
1.3 ( % & , & , )
2.3 ( & , & )
3.3 &
4.3 &
). " :
1. |
" % ( , , " |
|
& ) |
2.- " % , -
3." % ( % , ,, )
4.! ( , " , )
' % " , " , [ "$ : "$ ($), "$ "$.
* : ; % # (- , , ), %
, & |
|
||
, " |
$ (3 " |
||
<-J ); " " : |
|||
& % & , |
% |
||
"$ ( " @ % ). |
|
||
" |
: |
|
|
" |
: ; G " |
||
, |
" |
, |
|
|
, . |
|
5 : ? , ?6, , $.
: , $ . $# , " % – ;
, |
|
& – " |
; % |
– |
|
. |
|
|
" & : |
||
1. % 2 |
|
2.#
3.!-
4.< "
5."
6. < " "
7.;
8.O6 ; %
9.H)B
10.HbsAg, Anti-HCV.
" & & :
+ :
(-& )– . " &
& |
3- 4- |
|
|
|
|
|
( ), |
( ) |
|
|
|
|
|
( , , |
). H" $ & |
|||||
, $ $ " & |
, & |
" 24 " . ) 3 & "-"$ $ , " %, 3 , & & - . ' ( " ) .
% ,$ 3$" . V % % & ,&$# - , "- $# . " && - " 1-2 & # , " & & 3 .
; " " (G ) % & & & & V . ! &
|
& , |
, |
|
" |
G |
$ |
|
( & , |
" " |
). $" |
|||||
|
"-" |
|
G . |
! " |
|||
& |
, " 3 & |
||||||
|
" % , |
$ % ( , .) |
# ( ) . $ $ V ,( , , % " " %$# ). +& 3 3 " , ,. . . ' " 2-3 & &
. |
" $" $ |
|
. |
B$" |
|
$ " G , |
|
& . @ |
|||
" & ( ) " G |
|||||
" ( , " " ), |
-, |
||||
|
& & |
, |
|||
( ) &: |
, -& |
||||
& . @ "& 100% & |
-& |
( 3 , 3 , . .)% . B 3 " " &
3 ( , & , % , H_ ). & - 3 , " - & " G , " " # . B " # "
& . 7 &, , , " , . ., - $#& , & ( ) " . @ , " " , %$# & ( -& ) , &
& & , " G " % . "G $ ( &$) . & - & .
# ( ) " & G %$" & $# :
1.! & & ( " G - & % , % # , V . .).
2.H & % .
3. |
' & & % |
V . |
|
|
||
4. |
|
$ " . |
|
|
||
5. |
; |
|
% |
" |
% , |
|
"$# |
% & |
3 |
3 |
|
|
.
6.) & &" # % ", &- ( ," % ).
7.) 3 " , "
& " " 3 , % " & % & .
8. ) % && V % ( ).
9.' & " % &$ & - $ .
10." & & , 3 , , % ( % , " % , ,
% " ) 3 (" |
|
" ) & . |
|
11. J$ ( ) |
& G |
( " |
# , " - |
. - , "$ & , $# ,
$# |
" ) % & . |
12. _ |
" " |
& |
; & , |
" |
. |
13.".
14.+ # - &,.
! " $ ( |
|
" ) $" |
|||
|
|
|
. |
||
< & # , |
G % |
||||
$ |
" % . |
||||
' & % & |
( , |
|
|
|
). < & ,( & , ,), % " ,
( $" , & )." %" ,& " :, 3 & " " $# #" , " ,- & " , ,
& $# |
& |
. ' |
||||
|
|
, |
|
& |
||
" " & |
( |
3-4 |
, |
|||
, |
, |
, |
|
), |
||
|
|
( |
, , |
. |
, |
), $# "$# $ |
|
( , , |
$, .), (3 . , !) , |
|
, , ), , |
( ), "$ ( , |
|
, ', ?, !, >), ( , $). |
@ " |
|
|
& |
|
& 400 \ " 21 . ' |
||
|
, |
" (H_, |
|
3 , H'L- .), J_, " . % |
|||
% |
, & & |
||
" . |
|
" & :
1. |
*/ |
V 250 , 500 , 1 000 |
|
|
|
2. |
*? V 500 /2 |
|
3. |
*/ 250 , 500 |
|
4. |
*6 0,5 100 |
|
5. |
*B & 150 – 10 \ |
|
6. |
* , " , #$# (3 , |
|
|
!) , |
, , ) |
7.*? V 5%, 10% 2 , 5
8.* 1
9.*; V 5% 1
10.*/ V 1 (500 )
" & & :
,- ! :
" " .
/ , & :
1.?.?., !$& '.'. ";
2.http://www.clevelandclinic.org/health/, Osteomyelitis;
3.http://www.nlm.nih.gov/medlineplus, Osteomyelitis, 2004;
4.K ?. ., ! " & " ;
5.? M.?., < B.'. G " –" .
* – , # (% % ) .
' & 8 . # !
: 12-120 |
|
|
"$ &: " |
|
|
: |
|
|
& ! : & % |
|
|
' & & ( ): 18 |
|
|
(: N40 & % |
|
|
) : ' & 8 |
(';"W) - |
|
$ , |
$# |
|
& & % , |
# % " |
. @ @ D & " (1). " & "( " # " , " , & " , " , % ,
# # % " |
, ). |
|
$ : |
|
|
I - , |
" |
, " " . |
II - , |
" |
, " " " . |
III - , " , " V " " , " % " .
* : % , " , $#(G +, " )
" : 3
" & :
1.# (6 )
2.# "
3.( , , , " , " & , )
4."
5.$
7.;
8.
9."
10.7
11._ $
12.6
13.'
14.&
15.& "
16.H)B "
17.H)B "
18.H)B " "
19.HbsAg, Anti-HCV.
" & & :
1.H
2.H)B $
+ :